Community Series In Manipulating The Immunological Tumor Microenvironment Volume Ii

This Research Topic is the second volume of the “Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor". Please Volume I here. The microenvironment of tumors is consisted of the tumor stroma, proliferating tumor cells, infiltrating inflammatory cells, blood vessels, and various associated tissue cells. The pre-metastatic niche (PRN) is described as supportive and receptive, which undergoes cellular and molecular changes to form the fertile “soil” or metastatic-designated sites for metastatic tumor cell “seed” colonization. Thus, the PRN supports promoting tumor metastasis and tumor settlement in distant organs. The infiltration of the immune cells and the formation of blood vessels from the pre-metastatic sites are critical for the tumor microenvironment. Typically, the angiogenic factor is strongly associated with the inflammatory response during the development of tumors. Additionally, the immunoediting processes are essentially devoted to promoting angiogenesis and modulating the innate and specific immune responses.

This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.

This book, "Histopathology-An Update" is a comprehensive book that deals with the latest advances in the field of histopathology. This book will be of help to pathologists, clinicians and researchers in the latest update in histopathology of various organs.